AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Autolus Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.59−0.01 (-0.63%)
Close on Oct 19, 2026
- Market cap
- $423.19M
- P/E (TTM)
- –
- Dividend yield
- –
Autolus Therapeutics plc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $74.32M | $0 | $0 | – | – | – | 98.6% | – |
| License revenue | $1.07M | $10.12M | $1.70M | $6.19M | $1.51M | $242.00K | 1.4% | -89.4% |
| Royalty | $0 | $0 | $0 | $0 | $0 | $0 | 0.0% | – |
| Grant | – | – | $0 | $166.00K | $823.00K | $1.47M | – | – |
By region
From the segment and revenue-disaggregation notes of Autolus Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.